Prucalopride in diabetic and connective tissue disease-related gastroparesis: Randomized placebo-controlled crossover pilot trial.,Neurogastroenterology & Motility

当前位置： X-MOL 学术 › Neurogastroenterol. Motil. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Prucalopride in diabetic and connective tissue disease-related gastroparesis: Randomized placebo-controlled crossover pilot trial.
Neurogastroenterology & Motility ( IF 3.5 ) Pub Date : 2020-08-02 , DOI: 10.1111/nmo.13958
Christopher N Andrews ₁ , Matthew Woo ₁ , Michelle Buresi ₁ , Michael Curley ₁ , Milli Gupta ₁ , Jan Tack ₂ , Lynn Wilsack ₁ , Yasmin Nasser ₁

Affiliation

Gastroparesis, defined by delayed gastric emptying in the absence of mechanical outlet obstruction, is a frequent neuropathic complication of diabetes mellitus, and effective treatments are lacking. Prucalopride is a pan‐gut prokinetic with selective agonist effects on serotonin 5‐HT4 receptors in the gut. This study aimed to assess the effect of prucalopride 4 mg daily on Gastroparesis Cardinal Symptom Index (GCSI), meal‐related symptom score (MRSS), and gastric emptying rate in diabetic or connective tissue disease (CTD)‐related gastroparesis patients.

中文翻译：

Prucalopride 治疗糖尿病和结缔组织病相关胃轻瘫：随机安慰剂对照交叉试验。

胃轻瘫定义为在没有机械出口阻塞的情况下胃排空延迟，是糖尿病的常见神经性并发症，并且缺乏有效的治疗方法。Prucalopride 是一种全肠道促动力剂，对肠道中的 5-羟色胺 5-HT4 受体具有选择性激动剂作用。本研究旨在评估每天 4 mg 普卡必利对糖尿病或结缔组织病 (CTD) 相关胃轻瘫患者胃轻瘫主要症状指数 (GCSI)、进餐相关症状评分 (MRSS) 和胃排空率的影响。

更新日期：2020-08-02

点击分享查看原文

点击收藏

阅读更多本刊最新论文